Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x100px
Organisation › Details

Disco Pharmaceuticals Swiss GmbH

DISCO Pharma, operating out of Cologne, Germany and Schlieren, Switzerland, employs a disruptive scalable technology to map the surfaceome of cancer cells and develop first-in-class cancer drugs. With the advent of new cell-surface, target-directed therapeutic modalities (including ADCs and bi-specific antibodies), it is critical to ramp up the discovery of meaningful targets. DISCO does so by comprehensively identifying druggable targets, as well as protein communities (i.e., different proteins that form nanoscale organizations on a cell), across the entire cancer cell surface at scale, thus uncovering crucial new information that neither genome nor transcriptome sequencing can provide. By knowing which proteins are truly present on the cell surface, and how they are associated within protein communities, DISCO can design highly specific binders, boosting expected efficacy and reducing side effects. DISCO has a highly experienced team with a strong track record in cancer drug discovery and entrepreneurial value creation, as well as a deep understanding of surface proteomics born out of ETH in Zurich and developed further within the Company. DISCO is backed by world leading life sciences investors including Sofinnova Partners, Panakes Partners, M Ventures and AbbVie Ventures. *


Period Start 2023-08-18 established
  Group Disco Pharmaceuticals (Group)
  Predecessor ETH Zürich (ETHZ)
Product Industry  cancer drug
Region Region Schlieren ZH
  Country Switzerland
  Street 25 Wagistr.
  City 8952 Schlieren ZH
    Address record changed: 2024-01-17
Basic data Employees n. a.
    * Document for »About Section«: Disco Pharmaceuticals GmbH. (1/16/24). "Press Release: Disco Pharmaceuticals Launches as the Surfaceome Company with EUR 20 Million in Seed Financing". Cologne & Zurich.
Record changed: 2024-01-17


Picture Demy-Colton BioFuture 2024 NYC 3 Healthcare Revolution 650x200px

More documents for Disco Pharmaceuticals (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group World of Partnering Opportunities 650x300px

» top